Allogeneic stem cell transplantation in AML and MDS - Reduced conditioning for increased risk? The Munich/AMLCG approach

被引：0
作者：
Schmid, C. [1 ,2 ]
Schleuning, M.
Kolb, H. -J. [1 ,3 ]
机构：
[1] Munich Univ Hosp, Dept Med 3, Jose Carreras Unit Hematopoiet Stem Cell T, Munich, Germany
[2] GSF Munich, Res Ctr Environm & Hlth, Clin Cooperat Grp Stem Cell Transplantat, Munich, Germany
[3] Deutsch Klin Diagnost, Stem Cell Transplantat Unit, D-6200 Wiesbaden, Germany
来源：
ANNALS OF HEMATOLOGY | 2006年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 104
页数：4
相关论文
共 40 条
[1]   Who should be transplanted for AML? [J].
Appelbaum, FR .
LEUKEMIA, 2001, 15 (04) :680-682
[2]   Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey [J].
Arnold, R ;
de Witte, T ;
van Biezen, A ;
Hermans, J ;
Jacobsen, N ;
Runde, V ;
Gratwohl, A ;
Apperley, JF .
BONE MARROW TRANSPLANTATION, 1998, 21 (12) :1213-1216
[3]   TREATMENT OF MURINE LEUKAEMIA WITH X-RAYS AND HOMOLOGOUS BONE MARROW .2. [J].
BARNES, DWH ;
LOUTIT, JF .
BRITISH JOURNAL OF HAEMATOLOGY, 1957, 3 (03) :241-252
[4]   Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia [J].
Bertz, H ;
Potthoff, K ;
Finke, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1480-1484
[5]   BONE-MARROW TRANSPLANTS MAY CURE PATIENTS WITH ACUTE-LEUKEMIA NEVER ACHIEVING REMISSION WITH CHEMOTHERAPY [J].
BIGGS, JC ;
HOROWITZ, MM ;
GALE, RP ;
ASH, RC ;
ATKINSON, K ;
HELBIG, W ;
JACOBSEN, N ;
PHILLIPS, GL ;
RIMM, AA ;
RINGDEN, O ;
ROZMAN, C ;
SOBOCINSKI, KA ;
VEUM, JA ;
BORTIN, MM .
BLOOD, 1992, 80 (04) :1090-1093
[6]  
Büchner T, 1999, BLOOD, V93, P4116
[7]   Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].
Cassileth, PA ;
Harrington, DP ;
Appelbaum, FR ;
Lazarus, HM ;
Rowe, JM ;
Paietta, E ;
Willman, C ;
Hurd, DD ;
Bennett, JM ;
Blume, KG ;
Head, DR ;
Wiernik, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656
[8]   Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation [J].
de Lima, M ;
Anagnostopoulos, A ;
Munsell, M ;
Shahjahan, M ;
Ueno, N ;
Ippoliti, C ;
Andersson, BS ;
Gajewski, J ;
Couriel, D ;
Cortes, J ;
Donato, M ;
Neumann, J ;
Champlin, R ;
Giralt, S .
BLOOD, 2004, 104 (03) :865-872
[9]   Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS [J].
de Lima, M ;
Couriel, D ;
Thall, PF ;
Wang, XM ;
Madden, T ;
Jones, R ;
Shpall, EJ ;
Shahjahan, M ;
Pierre, B ;
Giralt, S ;
Korbling, M ;
Russell, JA ;
Champlin, RE ;
Andersson, BS .
BLOOD, 2004, 104 (03) :857-864
[10]  
Edenfield WJ, 1999, SEMIN ONCOL, V26, P21
1234